Device Venture Financings in 2005
This article was originally published in Start Up
Executive Summary
Trends in private device financing in 2005.
You may also be interested in...
Late-Stage Dealmaking Takes Off
Some VCs insist that only 25%-30% of device investments find a successful exit -- significantly better than the 10% of biotech deals, but still far from a sure thing. As a result, over the past year or so, there has been a marked increase in interest in late-stage dealmaking -- investments made at Series C or later or via alternative vehicles such as PIPE deals and SPACs.
Financing Private Biotechs in 2005: Following the Money
Analyzing VC investments in private companies last year suggests that conventional wisdom is holding: oncology and specialty pharma firms did especially well, pulling in the biggest shares of biopharma private equity in 2005.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.